Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition

Takamitsu Hattori¹,²*, Akiko Koide¹,³, Maria G. Noval⁴, Tatyana Panchenko¹, Larizbeth A. Romero², Kai Wen Teng¹, Takuya Tada⁴, Nathaniel R. Landau⁴, Kenneth A. Stapleford⁴ and Shohei Koide¹,²*

¹ - Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016, USA
² - Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY 10016, USA
³ - Department of Medicine, New York University Grossman School of Medicine, New York, NY 10016, USA
⁴ - Department of Microbiology, New York University Grossman School of Medicine, New York, NY 10016, USA

Correspondence to Takamitsu Hattori and Shohei Koide: Takamitsu.Hattori@nyulangone.org (T. Hattori), Shohei.Koide@nyulangone.org (S. Koide)

Abstract

The COVID-19 pandemic remains a global threat, and host immunity remains the main mechanism of protection against the disease. The spike protein on the surface of SARS-CoV-2 is a major antigen and its engagement with human ACE2 receptor plays an essential role in viral entry into host cells. Consequently, antibodies targeting the ACE2-interacting surface (ACE2IS) located in the receptor-binding domain (RBD) of the spike protein can neutralize the virus. However, the understanding of immune responses to SARS-CoV-2 is still limited, and it is unclear how the virus protects this surface from recognition by antibodies. Here, we designed an RBD mutant that disrupts the ACE2IS and used it to characterize the prevalence of antibodies directed to the ACE2IS from convalescent sera of 94 COVID-19-positive patients. We found that only a small fraction of RBD-binding antibodies targeted the ACE2IS. To assess the immunogenicity of different parts of the spike protein, we performed in vitro antibody selection for the spike and the RBD proteins using both unbiased and biased selection strategies. Intriguingly, unbiased selection yielded antibodies that predominantly targeted regions outside the ACE2IS, whereas ACE2IS-binding antibodies were readily identified from biased selection designed to enrich such antibodies. Furthermore, antibodies from an unbiased selection using the RBD preferentially bound to the surfaces that are inaccessible in the context of whole spike protein. These results suggest that the ACE2IS has evolved less immunogenic than the other regions of the spike protein, which has important implications in the development of vaccines against SARS-CoV-2.

Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide outbreak of the coronavirus disease 2019, COVID-19. As of October 25th 2020, over 42 million cases have been confirmed globally, leading to 1.1 million deaths (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/). A number of drugs and vaccines for COVID-19 are currently in clinical trials, yet no agents or vaccines have been approved by the
government agencies. As such, the host immune responses remain the main source of protection against the virus. Still many aspects of the immune responses and the strategies employed by the virus to evade them are unknown.

The entry of SARS-CoV-2 into host cells is mediated by a virus-surface spike glycoprotein that forms a trimer (Figure 1(A)). The spike protein is composed of two subunits, S1 and S2. The S1 subunit interacts with the host cell receptor, angiotensin-converting enzyme 2 (ACE2), a crucial step in cell attachment, whereas the S2 subunit plays a role in the fusion of the viral and cellular membrane, a crucial step in cell entry. The receptor binding domain (RBD) in the S1 subunit is the domain that binds ACE2 with an affinity in the low nanomolar range, and this interaction initiates the conformational change of the spike protein from the pre-fusion state to the post-fusion state. Consequently, antibodies targeting the ACE2-interacting surface (ACE2IS) located in the RBD of the spike protein can compete with the RBD-ACE2 interaction, serving as neutralizing antibodies. Indeed, such antibodies isolated from COVID-19 patients showed potent neutralization effects and are being developed as therapeutics. Thus, eliciting antibodies targeting the ACE2IS from the immune system should be critical for controlling and preventing COVID-19.

A region of an antigen is considered immunogenic if it is readily recognized by antibodies, although many aspects in the immune responses of the host can influence the overall immunogenicity. It has been shown that antibodies and antibody-like binders derived from unbiased selections disproportionately target functional surfaces of a protein. Thus, protein–protein interaction interfaces such as the ACE2IS in the RBD of the spike protein are expected to be highly immunogenic. From the viewpoint of viral evolution, there should be a strong selective pressure favoring the protection of a region that is crucial for the viral life-cycle from host immune attacks. For example, the CD4-binding site of the HIV gp120 envelope glycoprotein is situated in a deep cleft heavily protected by glycosylation. However, studies revealed that the spike proteins of coronavirus including SARS-CoV-2, SARS-CoV and MERS-CoV are less densely glycosylated than the other viral spike proteins including, HIV-1 envelope, Lassa virus glycoprotein complex, and influenza hemagglutinin envelop. In particular, the RBD is less shielded by glycans as compared with the rest of the spike protein of SARS-CoV-2. The RBD and the ACE2IS are the most distal parts of the spike protein in the assembled virus and thus it should be more accessible to antibodies and B-cells. Taken together, the ACE2IS of the SARS-CoV-2 is expected to be substantially more immunogenic than anticipated based on its surface exposure. Intriguingly, a number of studies of SARS-CoV-2 specific antibody responses in COVID-19 patients have revealed that, although most convalescent plasmas from COVID-19 patients contain antibodies targeting the spike protein and the RBD, they have low neutralization activity. Thus, analysis of the immunogenic surfaces, or the “immunogenicity landscape”, of the spike protein and the RBD in terms of eliciting high-affinity antibodies should provide important insights into the antibody response to COVID-19 as well as vaccine design, because the spike protein and the RBD are the antigens in most first-

Figure 1. Design of an RBD triple mutant that disrupts the ACE2IS. (A) The structure of the spike trimer (PDB 6VSB). The RBD in the up and down conformations are shown in blue and light blue, respectively. (B) The RBD in complex with ACE2 (PDB 6M0J). The RBD core is shown in blue and ACE2 is shown in green. The receptor binding motif in the RBD is shown in yellow, and the residues contacting ACE2 are shown in red. The dotted circles indicate contact regions (CR1, CR2 and CR3). The amino acid residues (N487, Q493 and N501) in the RBD are shown as stick model and labeled in red, and their contacting residues in ACE2 are labeled in black. (C) Binding titration of the RBD and RBD-T to ACE2 expressing A549 cells. Data shown here are from triplicate measurements. The $K_v$ values are from curve fitting of a 1:1 binding model, and the errors shown are the s.d. from curve fitting. Error bars are within the size of the symbols.
generation vaccines for COVID-19 (https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines).

In this study, to define immunogenic properties of epitopes within the spike protein, we performed in vitro selection of a synthetic human antibody library against the spike protein and the RBD. We designed an RBD mutant that abolished binding of the RBD to ACE2, and utilized it as a tool for epitope analysis of convalescent sera and in antibody discovery. Our results suggest that the ACE2IS in the RBD is a minimally immunogenic surface within the spike protein, and we discuss the molecular underpinning of this finding and its implications for vaccine design.

Results

Design of an RBD mutant that disrupts the ACE2IS

To develop a tool for facilitating the analysis of ACE2IS-binding antibodies, we designed an RBD mutant that disrupts the ACE2IS. The ACE2IS in the RBD is mainly composed of three contact regions, CR1, CR2 and CR3 (Figure 1(B)). From each contact region, we chose a key residue (N487, Q493 and N501) that forms hydrogen bond (s) with residues in ACE2, and mutated them to Lys residues to disrupt both electrostatic and van der Waals interactions (Figure 1(B), Supplementary Figure 1). We term this mutant as RBD-T hereafter. Binding analysis using ACE2-expressing cells showed that the RBD bound to ACE2 with high affinity ($K_D \sim 20$ nM), consistent with previous reports, and that RBD-T nearly completely lost binding to ACE2 (Figure 1(C)). Likewise, these mutations should disrupt binding of neutralizing antibodies targeting the ACE2IS (see below). We note that not all neutralizing antibodies would fail to bind to RBD-T, because some neutralizing antibodies do not directly bind to the ACE2IS.

A binding assay using the RBD and RBD-T is a straightforward method to determine whether antibodies recognize the ACE2IS or not, and thus we utilized the RBD-T as an epitope analysis tool for anti-RBD antibodies.

Analysis of convalescent serum using RBD-T

To characterize the prevalence of antibody response to the ACE2IS in COVID-19 patients, we performed binding analysis of 94 convalescent serum samples from healthcare workers who showed PCR-positivity for COVID-19. In this experiment, we measured the IgG binding to the RBD in the absence and presence of excess soluble RBD-T competitor. Strikingly, more than 60% of the signal was lost in the presence of the RBD-T competitor in 80% of the serum samples, indicating that the majority of the antibodies that bound to the RBD in convalescent sera did not target the ACE2IS (Figure 2(A) and (B)). We found that the neutralization titer is correlated with anti-RBD IgG binding but to a lesser degree with anti-RBD-T IgG binding (Figure 2(C)), confirming that IgG antibodies targeting the ACE2IS contribute to neutralization. Together, these data suggest that the ACE2IS is not a highly immunogenic epitope within the RBD.

Unbiased antibody selection for the spike protein and the RBD

To investigate the immunogenicity landscape of the spike protein and the RBD, we performed in vitro selection of a human antibody phage-display library against the spike protein and the RBD. The recovery of antibody clones in the in vitro selection primarily depends on the strength of binding to the antigen, and thus analyzing specificity and epitopes of enriched antibodies enables us to determine the immunogenicity landscape of the antigens from the point of the direct antibody-antigen interaction under well-defined conditions. We used a synthetic antibody library that is constructed based on both intrinsic amino acid bias in immune repertoires and knowledge of structures and functions of naturally occurring antibodies. This, and closely related antibody libraries, have generated numerous high-affinity antibodies to diverse proteins. Of importance for this study, this library uses the IGHV3 framework, which is closely related to the IGHV3-53 germline that is frequently found in RBD-binding antibodies (see Discussion).

We first performed selection for antibodies against the spike protein and the RBD in an unbiased manner, that is, we did not incorporate steps that might bias the recovery of antibodies binding to different epitopes. From the 3rd and 4th rounds of selection were randomly picked, and their sequences and binding specificity were characterized in the phage-display format. We identified 95 unique clones out of 120 randomly picked colonies from the spike selection campaign (Figure 3(A)). Strikingly, 89% of the clones bound to the spike protein but not the RBD or RBD-T (“Spike only” binders), indicating that these antibodies recognize the surfaces of the spike protein outside the RBD or the surfaces that partially consists of the RBD (Figure 3(A) and (B)). Only 11% of the clones showed ability to bind to the spike protein as well as the RBD and RBD-T (“Spike + RBD” binders), and antibodies binding to the ACE2IS, as judged by the ability to bind to the RBD but not to RBD-T, were not identified from this selection. These results suggest that the RBD is not a highly immunogenic region of the spike protein.

From the RBD selection campaign, we identified 23 unique clones out of 24 randomly picked colonies (Figure 3(A)). Although the ACE2IS is highly exposed on the RBD, antibodies targeting the ACE2IS were not identified from this selection.
Interestingly, 83% of the clones showed binding to the RBD and RBD-T, but not to the spike protein ("RBD only" binders) (Figure 3(A) and (B)). These data indicate that their epitopes are exposed when the RBD exists in isolation or after dissociation of the S1 subunit from the spike protein, but are not exposed when the RBD is a part of the fully assembled spike trimer. These results suggest that, if the RBD is used as an antigen for vaccination, antibodies targeting those epitopes of the RBD that are not exposed in the native spike protein can dominate in the initial immune response. Together, our data suggest that isolated RBD contains highly immunogenic epitopes that are inaccessible in the context of the fully assembled spike protein.

Biased antibody selection readily identifies ACE2IS-targeting antibodies

Because the unbiased RBD selection campaign enriched antibodies that do not bind to the spike protein, we next performed antibody selection using both RBD and spike protein as the antigens (Figure 3(A)) to intentionally enrich for clones that cross-react with both antigens. We identified 35 unique antibodies among 120 randomly chosen clones. A majority of clones bound to both RBD and spike protein ("Spike + RBD" binders), indicating that RBD contains epitopes that can be readily recognized in the context of the fully assembled spike protein (Figure 3(A) and (B)). We note that antibodies that bound outside the RBD ("Spike only" binders) and to epitopes on the RBD that are inaccessible in the spike protein ("RBD only" binders) were still recovered, despite the use of a strong selection bias against such clones. We identified clones that bound to both RBD and spike protein but not RBD-T, indicating that they recognize the ACE2IS ("ACE2IS binders"). Interestingly, among RBD-binding antibodies, only 12% of clones recognize the ACE2IS in the RBD, whereas 88% of clones recognize epitopes other than the ACE2IS (Figure 3(A) and (B)). These data are consistent with what we observed in the analysis of antibodies in convalescent sera (Figure 2(A) and (B)) and suggest that the ACE2IS deflects antibody recognition.
We next performed selection of antibodies binding to the RBD that incorporated a negative selection step using RBD-T so as to enrich antibodies binding to the ACE2IS. From this selection, 39% of clones recognized the ACE2IS in the RBD, which is a substantially higher percentage than those recovered in the unbiased selections (0% for both selections using the spike protein and the RBD) as well as the RBD-spike selection (11%) (Figure 3(A)). These data indicate that our phage-display library contains antibodies targeting the ACE2IS and such antibodies can be identified if we intentionally try to enrich such antibodies. Taken together, our data demonstrate that the RBD is not a dominant immunogenic domain in the spike protein and the ACE2IS is a minimally immunogenic epitope within the RBD.

Screening for a loss of binding to RBD-T identifies neutralizing antibodies

To determine whether antibodies that do not bind to RBD-T, i.e. ACE2IS binders, indeed neutralize SARS-CoV-2, we produced five Fab clones (one each from “Spike only”, “Spike + RBD” and “RBD only” binders and two from ACE2IS binders), and we performed the binding assay, the competitive binding assay with ACE2 and the neutralizing assay using authentic SARS-CoV-2. The antibodies targeting the spike protein outside the RBD (A4-2) and targeting the RBD outside the ACE2IS (B3-4 and B3-1) did not interfere with the ACE2-spike interaction nor did show a neutralization effect (Figure 3(C)–(E)). In contrast, ACE2IS binders (C3-3 and C4-3) that bound to

| Selection Target used (1st-2nd-3rd-4th rounds) | Number of picked colonies | Number of binding-positive & unique clones | Number of binders |
|-----------------------------------------------|---------------------------|------------------------------------------|-------------------|
| A Spike-Spike-Spike-Spike                    | 120                       | 95 (89%)                                 | 0 (0%)            |
| B RBD-RBD-RBD-RBD                            | 24                        | 23 (0%)                                  | 19 (83%)          |
| BB RBD-RBD-Spike-Spike                       | 120                       | 35 (3%)                                  | 7 (20%)           |
| C RBD-RBD-RBD-RBD                            | 24                        | 18 (0%)                                  | 6 (33%)           |

| Clone Type | Spike only | RBD only | Spike + RBD | ACE2IS binder |
|------------|------------|----------|-------------|---------------|
| A4-2       |            |          |             |               |
| B3-4       |            |          |             |               |
| B3-1       |            |          |             |               |
| C3-3       |            |          |             |               |

| Clone Type | Spike only | RBD only | RBD-T | No target |
|------------|------------|----------|-------|-----------|
| A4-2       |            |          |       |           |
| B3-4       |            |          |       |           |
| B3-1       |            |          |       |           |
| C3-3       |            |          |       |           |

| Fab conc. (nM) | MFI (x10^5) |
|----------------|-------------|
| 0              | 0           |
| 2              | 2           |
| 4              | 4           |
| 6              | 6           |
| 8              | 8           |
| 10             | 10          |

| Fab conc. (nM) | MFI (x10^5) |
|----------------|-------------|
| 0              | 0           |
| 2              | 2           |
| 4              | 4           |
| 6              | 6           |
| 8              | 8           |
| 10             | 10          |

| Fab conc. (nM) | MFI (x10^5) |
|----------------|-------------|
| 0              | 0           |
| 2              | 2           |
| 4              | 4           |
| 6              | 6           |
| 8              | 8           |
| 10             | 10          |

| Fab conc. (nM) | MFI (x10^5) |
|----------------|-------------|
| 0              | 0           |
| 2              | 2           |
| 4              | 4           |
| 6              | 6           |
| 8              | 8           |
| 10             | 10          |

| Fab conc. (nM) | MFI (x10^5) |
|----------------|-------------|
| 0              | 0           |
| 2              | 2           |
| 4              | 4           |
| 6              | 6           |
| 8              | 8           |
| 10             | 10          |

| Fab conc. (nM) | MFI (x10^5) |
|----------------|-------------|
| 0              | 0           |
| 2              | 2           |
| 4              | 4           |
| 6              | 6           |
| 8              | 8           |
| 10             | 10          |

| Fab conc. (nM) | MFI (x10^5) |
|----------------|-------------|
| 0              | 0           |
| 2              | 2           |
| 4              | 4           |
| 6              | 6           |
| 8              | 8           |
| 10             | 10          |

| Fab conc. (nM) | MFI (x10^5) |
|----------------|-------------|
| 0              | 0           |
| 2              | 2           |
| 4              | 4           |
| 6              | 6           |
| 8              | 8           |
| 10             | 10          |

We next performed selection of antibodies binding to the RBD that incorporated a negative selection step using RBD-T so as to enrich antibodies binding to the ACE2IS. From this selection, 39% of clones recognized the ACE2IS in the RBD, which is a substantially higher percentage than those recovered in the unbiased selections (0% for both selections using the spike protein and the RBD) as well as the RBD-spike selection (11%) (Figure 3(A)). These data indicate that our phage-display library contains antibodies targeting the ACE2IS and such antibodies can be identified if we intentionally try to enrich such antibodies. Taken together, our data demonstrate that the RBD is not a dominant immunogenic domain in the spike protein and the ACE2IS is a minimally immunogenic epitope within the RBD.
the RBD but not to RBD-T indeed competed with ACE2-spike interaction and showed a neutralization effect against the SARS-CoV-2 virus (Figure 3(C)–(E)), as we predicted. Thus, although we note that some neutralizing antibodies that do not directly target the ACE2IS have been reported,20 our binding assay using RBD-T is effective in quantifying neutralizing antibodies that target the ACE2IS.

Discussion

We have shown that the ACE2IS is more difficult to target with our synthetic antibody library than the rest of the RBD and the spike protein. Because no synthetic library can completely recapitulate the human antibody repertoire, one might view that these results are a reflection of limitations of our library, rather than the antigenic landscape of the spike protein. The following considerations strongly suggest that this is not the case. Neutralizing anti-RBD antibodies from recovered patients show clear biases in germline usage. The IGHV3-53 germline is the most frequently used IGHV gene for neutralizing anti-RBD antibodies and the residues in CDRH1 and CDRH2 encoded by the IGHV3-53 germline are important for RBDbinding.24 Our synthetic antibody library is based on the human V3 germline sequence, and residues in CDRH1 and H2 are diversified based on intrinsic amino acid bias in native immune repertoires.21,22 It has only minor differences, two substitutions in CDRH1 and a single residue insertion in CDRH2, from IGHV3-53 (Supplementary Table 1). Thus, our library should be more predisposed to generating anti-RBD neutralizing antibodies than a library that faithfully recapitulates the human antibody diversity. More importantly, we have identified several antibodies binding to ACE2IS by utilizing biased selection (Figure 3(A)). If the architecture of our library were substantially mismatched to the germline sequences required for RBDbinding, our ACE2IS-binding antibodies would be rare clones containing unusual sequences that are not expected from our library design. However, the sequences of the ACE2IS-binding clones match our library design (Supplementary Figure 3 and Supplementary Table 1), suggesting that we should find many clones if the ACE2IS were highly immunogenic. Taken together, although our library does not fully recapitulate human antibody repertoires, it covers a large fraction of the antibody sequence space capable of producing anti-RBD antibodies.

Why is the RBD difficult to target when whole spike trimer is used as the antigen? Our data suggest that the spike protein has highly immunogenic surfaces outside the RBD, which enrich antibodies that target these epitopes and deplete antibodies to the RBD. The structure and conformational dynamics of the spike protein offer possible mechanistic basis for the low immunogenicity of the RBD. The RBD in the up conformation is largely exposed on the spike surfaces, whereas the RBD in the down conformation is buried in the spike protein (Figures 1(A) and 4(A)). Structural studies of the spike protein revealed that zero, one or two RBDs but not all three RBDs in the spike trimer form the up conformation at a given time.1,2,25,26 Consequently, the RBD is largely in the down conformation and most of the RBD is less exposed than the rest of the spike surfaces (Figure 4(A)). Furthermore, it has been reported that the RBD in the up conformation shows higher mobility than that in the down conformation.25 Thus, both a lack of the complete exposure of the RBD and conformational mobility of the RBD probably contribute to the challenges in recognizing the RBD by antibodies when the spike protein is used as the antigen.

Our data indicate that the ACE2IS is minimally immunogenic within the RBD, although the ACE2IS is expected to be a highly immunogenic surface as discussed above, and is highly accessible when the RBD is in the up conformation. One possible explanation for the minimal immunogenicity of the ACE2IS is its conformational flexibility. Although the ACE2IS is well defined when bound to ACE2 or to an antibody, it is disordered in the free spike structures (Figure 4(B)).1,2,4,27–30 suggesting that the ACE2IS is inherently flexible. It is difficult to generate antibodies to a flexible region, due to a large loss of conformational entropy upon binding that disfavors binding. Taken together, we propose that limited surface exposure and flexibility of the ACE2IS reduces its immunogenicity in the spike protein.

Our studies have important implications for vaccine design. Most of vaccine candidates utilize the spike protein or the RBD as antigens (https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines). In our studies, 89% of antibodies from the unbiased selection for the spike protein recognize regions outside the RBD, and 83% of antibodies from the unbiased selection for the RBD recognize the surfaces on the RBD that are inaccessible in the context of the spike protein. These data imply that potent neutralizing antibodies targeting the ACE2IS may not be induced efficiently by only immunizing with the spike protein or only with the RBD. Consistent with this view, it has been reported that the majority of spike-binding antibodies that were generated in a patient during the first weeks of COVID-19 infection were not neutralizing and bind outside the RBD.31 Similarly, Juno et al. observed a high frequency of B cells that target the spike protein outside the RBD in recovered patients with COVID-19.18 Our data demonstrate that the ACE2IS can be readily targeted by antibodies in the biased selection. Although such control of the
human immune responses using designed antigens is impossible in the course of natural infection, we envision that a two-step vaccination scheme using the RBD followed by the spike protein could improve the efficiency of eliciting antibodies targeting the ACE2IS that confer strong viral neutralization.

**Materials and Methods**

**Plasmid construction**

The amino acid sequence of the ectodomain of the spike protein (residues 16–1213) was collected from GenBank entry MN908947.3. A codon-optimized gene encoding the spike protein with modifications reported by Amanat et al.,22 including stabilized mutations (K986P and V987P), the removal of the furin site (RRAR to A) and the addition of a T4 foldon trimerization domain, a hexahistidine tag and an Avitag at the C-terminus was synthesized (Integrated DNA Technologies) and cloned into the mammalian expression vector pBCAG. The codon-optimized genes encoding the receptor binding domain (RBD) of SARS-CoV-2 (residues 328–531; GenBank entry: MN908947.3) and a triple mutant (N487K/Q493K/N501K) of the RBD of SARS-CoV-2 with the hexahistidine tag and the Avitag at the C-terminus were synthesized (Integrated DNA Technologies) and cloned into the pBCAG vector.

**Mammalian cell culture**

The A549 cells stably expressing the angiotensin-converting enzyme 2 (ACE2) on the cell surface were maintained in Dulbecco’s Modified Eagle's Medium (DMEM, Thermo Fisher) supplemented with 2 μg/ml puromycin (InvivoGen), 10% fetal bovine serum (FBS, Gemini Bio) and penicillin/streptomycin (Thermo Fisher) at 37 °C with 5% CO2. The HEK293T cells stably expressing ACE2 on the cell surface were generated previously,17,33 and maintained in DMEM (Thermo Fisher) supplemented with 1 μg/ml puromycin (InvivoGen), 10% FBS (Gemini Bio) and penicillin/streptomycin (Thermo Fisher) at 37 °C with 5% CO2. The Vero E6 kidney epithelial cells were maintained in DMEM (Corning), 10% FBS (Atlanta biologicals) and 1% Nonessential Amino Acids (NEAA, Corning) at 37 °C with 5% CO2. The Expi293F cells (Thermo Fisher) were maintained in Expi293 Expression Medium (Thermo Fisher) at 37 °C with 8% CO2.

**Virus preparation**

icSARS-CoV-2-mNG (isolate USA/WA/1/2020, obtained from the UTMB World Reference Center
for Emerging Viruses and Arboviruses) was amplified once in Vero E6 cells (P1 from the original stock). Briefly, 90–95% confluent T175 flask (Thomas Scientific) of Vero E6 (1×10⁶ cells) was infected with 50 μL of iCSARS-CoV-2-mNG in 5 mL of infection media (DMEM, 2% FBS, 1% NEAA, and 10 mM HEPES) for 1 h. After 1 h, 20 mL of infection media was added to the inoculum and cells were incubated 72 h at 37 °C and 5% CO₂. After 72 h, the supernatant was collected and the monolayer was frozen and thawed once. Both supernatant and cellular fractions were combined, centrifuged for 5 min at 1200 rpm, and filtered using a 0.22 μm Steriflip (Millipore). Viral titers were determined by plaque assay in Vero E6 cells. In brief, 220,000 Vero E6 cells/well were seeded in a 24 well plate, 24 h before infection. Ten-fold dilutions of the virus in DMEM (Corning) were added to the Vero E6 monolayers for 1 h at 37 °C. Following incubation, cells were overlaid with 0.8% agarose in DMEM containing 2% FBS (Atlanta biologicals) and incubated at 37 °C for 72 h. The cells were fixed with 10% formalin, the agarose plug removed, and plaques visualized by crystal violet staining.

Serum samples

Serum samples were collected from 94 Healthcare workers from NYU Langone Health who showed PCR-positive for COVID-19, as reported previously. All patients gave written consent for this study and all samples were de-identified by following IRB #i20-00595.

Expression and purification of recombinant proteins

The expi293F cells (Thermo Fisher) were transiently transfected with the vectors using the ExpiFectamine 293 Transfection kit (Thermo Fisher) according to the manufacturer’s protocol. The cells were incubated at 37 °C with 8% CO₂ for 7 days. The cell culture supernatants were collected by centrifuge, and supplemented with a protease inhibitor cocktail (Roche) and 1 mM PMSF. The recombinant proteins were purified from the filtrated supernatants using a HisTrap excel column (GE Healthcare). The purified proteins were biotinylated in vitro using the BirA enzyme in the presence of 0.5 mM Biotin and 10 mM ATP. The biotinylated proteins were further purified using the HisTrap excel column, and dialyzed into PBS. Purity of proteins were confirmed by SDS-PAGE analysis. The size exclusion chromatography using a Superdex 200 10/300 (GE Healthcare) for the spike protein and a Superdex 75 10/300 (GE Healthcare) for the RBD and the RBD triple mutant showed a monodispersed and single peak with the expected molecular mass (Supplementary Figure 1).

Cell-based binding assay

The A549-ACE2 cells were detached from the flask using the citric saline buffer containing 15 mM sodium citrate and 135 mM KCl. The cells were washed with PBS twice and suspended in PBS-BSA (PBS containing 1% (w/v) BSA (Gemini Bio)). The cells were aliquoted into the wells of the 96-well round bottom plate (Greiner). The RBD and the RBD triple mutant were added to the wells containing the ACE2-A549 cells and incubated for 30 min at room temperature. The cells were washed three times with 200 μL of PBS-BSA, and incubated with Streptavidin-Dylight650 (Thermo Fisher) for 30 min at 4 °C. The cells were further washed three times with PBS-BSA and analyzed on an iQue screener (Satorius). For the competitive binding assay, the spike protein at a final concentration of 20 nM was incubated with 1 μM Fab clones or buffer for 30 min. The mixtures were added to the detached HEK293T-ACE2 cells and incubated for 30 min at room temperature. The cells were washed three times with 200 μL of PBS-BSA, and incubated with 6x-His Tag antibody-Dylight650 (Thermo Fisher) for 30 min at 4 °C. The cells were further washed three times with PBS-BSA and analyzed on an iQue screener (Satorius). Signals reported are the median fluorescence intensities.

Serum characterization

Antibody binding was characterized using a bead-based binding assay generally following our previous publications. Biotinylated RBD was conjugated to Dynabeads M—280 streptavidin (Thermo Fisher Scientific) as follows. Ten microliters of the stock bead suspension were mixed with 90 μL of PBSB (PBS containing 0.1% (w/v) BSA (GeminiBio)). The supernatant was removed using a magnetic stand and the beads were resuspended in 100 μL of PBSB. The beads were mixed with the equal volume of PBSB containing 15 nM of biotinylated RBD or biotinylated RBD-T and incubated at room temperature for 30 min. Biotin at a final concentration of 2.5 μM was then added to the solution and incubated for 5 min. The beads were washed three times with PBSB and analyzed on an iQue screener (Satorius). Signals reported are the median fluorescence intensities.

Synthetic human antibodies in the biotinylated format were expressed and purified as described previously.

Establishment of ACE2-expressing A549 cells

A549 cells were transfected with pLenti.ACE2 lentiviral vector that encodes ACE2 and puromycin resistance. After two days, the cells were selected in medium containing 2 μg/ml puromycin and cloned at limiting dilution. Individual cell clones were screened by flow cytometry for high ACE2 expression and a single cell clone was expanded.

Serum characterization

Antibody binding was characterized using a bead-based binding assay generally following our previous publications. Biotinylated RBD was conjugated to Dynabeads M—280 streptavidin (Thermo Fisher Scientific) as follows. Ten microliters of the stock bead suspension were mixed with 90 μL of PBSB (PBS containing 0.1% (w/v) BSA (GeminiBio)). The supernatant was removed using a magnetic stand and the beads were resuspended in 100 μL of PBSB. The beads were mixed with the equal volume of PBSB containing 15 nM of biotinylated RBD or biotinylated RBD-T and incubated at room temperature for 30 min. Biotin at a final concentration of 2.5 μM was then added to the solution and incubated for 5 min. The beads were washed three times with PBSB and analyzed on an iQue screener (Satorius). Signals reported are the median fluorescence intensities.
were washed once using a magnetic stand and resuspended at 0.5 mg/ml.

Five microliters of the beads were aliquoted in each well of a 96-well filter plate (Millipore), the liquid was removed using a vacuum chamber and the wells were washed once with 150 µL of PBST containing 1% (w/v) skim milk. Serum samples were heat-treated at 56 °C for 1 h and diluted 158-fold in PBST containing 1% (w/v) skim milk, and 25 µL each was added to the plate. For competition reactions, biotinylated RBD-T and streptavidin were mixed in such a way that all the biotin binding sites of streptavidin (tetramer) were occupied with RBD-T, and the complex was added to the serum solutions at a final concentration of 1 µM (calculated as monomer). After incubation for 30 min at room temperature with mixing on a shaker, the wells were washed twice with 150 µL of PBST-BSA (PBS containing 0.5% (w/v) BSA and 0.05% (v/v) Tween 20). The staining with a secondary antibody (anti-human IgG (FC gamma specific)-Alexa488, Jackson Immunoresearch) was blocked with biotin and then excess biotin binding sites of streptavidin were blocked with biotin. The biotinylated Fab clones were titrated into the solution containing the antigen-coated beads in the presence of 5 µM biotin, and incubated for 30 min at room temperature. After washing step, the beads were incubated with anti-human F(ab')2-Alexa Fluor 488 (Jackson ImmunoResearch). The beads were further washed three times and analyzed on an iQue screener (Sartorius). Signals reported are the median fluorescence intensities.

**Phage display antibody selection**

Sorting of a synthetic antibody library was performed as described previously. Briefly, a synthetic human antibody library was sorted against the antigens listed in the Figure 3(A), at the concentrations of 100 nM (1st round), 100 nM (2nd round), 50 nM (3rd round) and 20 nM (4th round). In the biased selection using RBD-T as the antigen for negative selection, biotinylated RBD-T was immobilized on the Streptavidin MagneSphere particles (Promega) and added to the solution containing phage. Phage bound to the RBD-T beads were removed prior to the selection against the antigens.

**Phage ELISA**

Phage ELISA was performed as described previously except that the 384-well plate was used instead of the 96-well plate. Briefly, the wells of the 384-well ELISA plate (Nunc) were coated with neutravidin (Thermo Fisher) for 1 h at room temperature. The wells were washed with PBS-T (PBS containing 0.1% Tween 20) and blocked with PBS containing 0.5% (w/v) BSA (Gemini Bio) for 1 h. After removing the blocking buffer, biotinylated antigens were added to each well and washed three times with PBS-T. The 5-fold dilution of the cell culture supernatants containing phage were added to the wells and incubated for 30 min. After washing the wells with PBS-T three times, anti-M13HRP (Sino Biological) was added to the wells. SIGMAFAST™ OPD (Sigma) was used as a substrate and 2 M HCl was used as a quenching solution. The absorbance at 490 nm was measured using a BioTek Epoch 2 plate reader (BioTek).

**Binding assay of Fab clones**

Binding titration of the Fab clones were performed by a bead binding assay, as described previously. Briefly, biotinylated antigens were immobilized on Dynabeads M-280 streptavidin (Thermo), and then excess biotin binding sites of streptavidin were blocked with biotin. The biotinylated Fab clones were titrated into the solution containing the antigen-coated beads in the presence of 5 µM biotin, and incubated for 30 min at room temperature. After washing step, the beads were incubated with anti-human F(ab')2-Alexa Fluor 488 (Jackson ImmunoResearch). The beads were further washed three times and analyzed on an iQue screener (Sartorius). Signals reported are the median fluorescence intensities.

**SARS-CoV-2 neutralization assay with Fab clones**

Vero E6 cells (30,000 cells/well) were seeded in a 96 well plate 24 h before infection. Biotinylated Fab clones were mixed with streptavidin produced in house, and diluted in DMEM (Corning), 2% FBS (Atlanta biological), 1% NEAA (Corning) and 10 mM HEPES (Gibco). Fifty nanomolar of the Fab-streptavidin complexes were mixed 1:1 (vol/vol) with SARS-CoV-2 virus (5.5 × 10⁵ PFU/ml, MOI 0.5), and incubated for 1 h at 37 °C. During the incubation period, Vero E6 monolayers were washed once with DMEM (Corning) to remove any serum present in the media that could interfere with the assay. After incubation, 100 µL of the mixtures of the antibody and SARS-CoV-2 were added to the Vero E6 monolayers, and cells were incubated at 37 °C. After 20 h, cells were fixed with 4 % formaldehyde (Electron Microscopy Sciences) at room temperature for 1 h. After fixation cells were washed twice with PBS and permeabilized with 0.25% Triton-100, stained with DAPI (Thermo), and quantified on a CellInsight CX7 High-content microscope (Thermo) using a cut-off for three standard deviations from negative to be scored as an infected cell.

**CRediT authorship contribution statement**

Takamitsu Hattori: Conceptualization, Investigation, Writing - original draft, Writing - review & editing. Akiko Koide: Investigation, Writing - review & editing. Maria G. Noval: Investigation, Writing - review & editing. Tatyana Panchenko: Investigation, Writing - review & editing. Larizbeth A. Romero: Investigation,
Writing - review & editing. **Kai Wen Teng:** Investigation, Writing - review & editing. **Takuya Tada:** Resources, Writing - review & editing. **Nathaniel R. Landau:** Resources, Writing - review & editing. **Kenneth A. Stapleford:** Investigation, Writing - review & editing. **Shohei Koide:** Conceptualization, Investigation, Writing - original draft, Writing - review & editing.

**Acknowledgments**

We would like to thank all the volunteers for participation and Drs. Maria E. Aguero-Rosenfeld and Joan Cangialarella and NYU Langone Hospital Outpatient Laboratory for serum sample collection; Dr. Florian Krammer for making the preprint of his paper available; Dr. Jonathan Lai for guidance for the preparation of the spike protein. This work was supported in part by the National Institute of Health grants R21 AI158997, R01 CA194864 and R01 CA212608 to S.K., DP1 DA046100, R33 AI122390 and K08 AI120898 to N.R.L., and R21 CA246457 to T.H. K.W.T. was supported by the American Heart Association Postdoctoral Fellowship 19-A0-00-1003686. T.T. was supported by the Vilcek/Goldfarb Fellowship Endowment Fund.

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**Appendix A. Supplementary material**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jmb.2020.166748.

Received 11 September 2020; Accepted 3 December 2020; Available online 11 December 2020

**Keywords:**

antibody-antigen interaction; ACE2-interacting surface; spike glycoprotein; receptor binding domain; COVID-19

**References**

1. Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.L., Abiona, O., et al., (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*, 367, 1260–1263.
2. Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., Veesler, D., (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell*, 181 281-92.e6.
3. Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., et al., (2020). Cell entry mechanisms of SARS-CoV-2. *Proc. Natl. Acad. Sci. USA*, 117, 11727–11734.
4. Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., et al., (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature*, 581, 215–220.
5. Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., et al., (2020). Structural basis of receptor recognition by SARS-CoV-2. *Nature*, 581, 221–224.
6. Hansen, J., Baum, A., Pascal, K.E., Russo, V., Giordano, S., Wloda, E., et al., (2020). Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science*, 369, 1010–1014.
7. Wec, A.Z., Wrapp, D., Herbert, A.S., Maurer, D.P., Haslwanter, D., Sakhrkar, M., et al., (2020). Broad neutralization of SARS-related viruses by human monoclonal antibodies. *Science*, 369, 731–736.
8. Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., et al., (2020). Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*, 584, 115–119.
9. Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., et al., (2020). A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. *Nature*, 584, 120–124.
10. DeLano, W.L., Ullsch, M.H., de Vos, A.M., Wells, J.A., (2000). Convergent solutions to binding at a protein-protein interface. *Science*, 287, 1279–1283.
11. DeLano, W.L., (2002). Unraveling hot spots in binding interfaces: progress and challenges. *Curr. Opin. Struct. Biol.*, 12, 14–20.
12. Kwong, P.D., Wyatt, R., Robinson, J., Sweet, R.W., Sodroski, J., Hendrickson, W.A., (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. *Nature*, 393, 648–659.
13. Watanabe, Y., Berndsen, Z.T., Raghwani, J., Seabright, G. E., Allen, J.D., Pybus, O.G., et al., (2020). Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. *Nature Commun.*, 11, 2688.
14. Watanabe, Y., Allen, J.D., Wrapp, D., McLellan, J.S., Crispin, M., (2020). Site-specific glycan analysis of the SARS-CoV-2 spike. *Science*, 369, 330–333.
15. Grant, O.C., Montgomery, D., Ito, K., Woods, R.J., (2020). Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition. *Sci. Rep.*, 10, 14991.
16. Robbiani, D.F., Gaebler, C., Muecksch, F., Lorenzi, J.C.C., Wang, Z., Cho, A., et al., (2020). Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature*, 584, 437–442.
17. Noval, M.G., Kaczmarek, M.E., Koide, A., Rodriguez-Rodriguez, B.A., Louie, P., Tada, T., et al., (2020). High titters of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding domain and nucleoprotein associate with better neutralization. *bioRxiv*, https://doi.org/10.1101/2020.08.15.252353.
18. Juno, J.A., Tan, H.X., Lee, W.S., Reynaldi, A., Kelly, H.G., Wragg, K., et al., (2020). Humoral and circulating follicular
helper T cell responses in recovered patients with COVID-19. Nature Med., 26, 1428–1434.

19. Wang, Y., Liu, M., Gao, J., (2020). Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions. Proc. Natl. Acad. Sci. USA, 117, 13967–13974.

20. Gavor, E., Choong, Y.K., Er, S.Y., Sivaraman, H., Sivaraman, J., (2020). Structural basis of SARS-CoV-2 and SARS-CoV antibody interactions. Trends Immunol., 41, 1006–1022.

21. Fellouse, F.A., Esaki, K., Birtalan, S., Raptis, D., Cancasci, V.J., Koide, A., et al., (2007). High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. J. Mol. Biol., 373, 924–940.

22. Miller, K.R., Koide, A., Leung, B., Fitzsimmons, J., Yoder, B., Yuan, H., et al., (2012). T cell receptor-like recognition of tumor in vivo by synthetic antibody fragment. PLoS One, 7, e43746.

23. Hornsby, M., Paduch, M., Miersch, S., Saaf, A., Matsuguchi, T., Lee, B., et al., (2015). A high through-put platform for recombinant antibodies to folded proteins. Mol. Cell Proteom., 14, 2833–2847.

24. Yuan, M., Liu, H., Wu, N.C., Lee, C.D., Zhu, X., Zhao, F., et al., (2020). Structural basis of a shared antibody response to SARS-CoV-2. Science, 369, 1119–1123.

25. Gur, M., Taka, E., Yilmaz, S.Z., Kilinc, C., Aktas, U., Golcuk, M., (2020). Conformational transition of SARS-CoV-2 spike glycoprotein between its closed and open states. J. Chem. Phys., 153, 075101.

26. Ke, Z., Oton, J., Ou, K., Cortese, M., Zila, V., McKeane, L., et al., (2020). Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature, 588, 498–502.

27. Hsieh, C.L., Goldsmith, J.A., Schaub, J.M., DiVenere, A. M., Kuo, H.C., Javanmardi, K., et al., (2020). Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science, 369, 1501–1505.

28. Pinto, D., Park, Y.J., Beltramello, M., Wallis, A.C., Tortorici, M.A., Bianchi, S., et al., (2020). Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature, 583, 290–295.

29. Henderson, R., Edwards, R.J., Mansouri, K., Janowska, K., Stalis, V., Gobell, S.M.C., et al., (2020). Controlling the SARS-CoV-2 spike glycoprotein conformation. Nature Struct. Mol. Biol., 27, 925–933.

30. Liu, Y.M., Shahed-Al-Mahmud, M., Chen, X., Chen, T.H., Liao, K.S., Lo, J.M., et al., (2020). A carbohydrate-binding protein from the edible lablab beans effectively blocks the infections of influenza viruses and SARS-CoV-2. Cell. Rep., 32, 108016.

31. Seydoux, E., Homad, L.J., MacCamy, A.J., Parks, K.R., Hurfburt, N.K., Jennewein, M.F., et al., (2020). Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation. Immunity, 53 98-105 e5.

32. Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T.H. O., Chromikova, V., McMahon, M., et al., (2020). A serological assay to detect SARS-CoV-2 seroconversion in humans. Nature Med., 26, 1033–1036.

33. Tada, T., Fan, C., Kaur, R., Stapleford, K.A., Gristick, H., Nimigean, C., et al., (2020). A soluble ACE2 microbody protein fused to a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2 infection in cell culture. bioRxiv, https://doi.org/10.1101/2020.09.16.300319.

34. Xie, X., Muruato, A., Lokugamage, K.G., Narayanan, K., Zhang, X., Zou, J., et al., (2020). An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe, 27 841-8 e3.

35. Nishikori, S., Hattori, T., Fuchs, S.M., Yasui, N., Wojcik, J., Koide, A., et al., (2012). Broad ranges of affinity and specificity of anti-histone antibodies revealed by a quantitative peptide immunoprecipitation assay. J. Mol. Biol., 424, 391–399.

36. Nady, N., Gupta, A., Ma, Z., Swigut, T., Koide, A., Koide, S., et al., (2015). ETO family protein Migt1 mediates Prdm14 functions in stem cell maintenance and primordial germ cell formation. Elife, 4, e10150.

37. Hattori, T., Lai, D., Dementieva, I.S., Montano, S.P., Kurosawa, K., Zheng, Y., et al., (2016). Antigen clamping by two antigen-binding sites of an exceptionally specific antibody for histone methylation. Proc. Natl. Acad. Sci. USA, 113, 2092–2097.